GlassScriptPhysician profile
Mallory Renae Hale
NPI 1235600156
$8,076.74
in general payments reported to CMS, 2019-2025
26 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $961 · 2022: $978 · 2023: $2,057 · 2024: $2,097 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,010 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,009.69 |
| Education | $127.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,018.41 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $828.17 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $701.57 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $679.75 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $630.94 | 2021-2025 | Lybalvi, Aristada |
| Validus Pharmaceuticals LLC | $509.82 | 2021-2025 | Equetro, Equetro, Raldesy |
| Otsuka America Pharmaceutical, INC. | $495.94 | 2021-2025 | Rexulti |
| Corium, LLC | $472.05 | 2023-2025 | Azstarys |
| Lundbeck LLC | $463.26 | 2021-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $327.31 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.53 | 2021-2025 | Trintellix |
| Abbvie INC. | $296.84 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $256.88 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $247.93 | 2021-2025 | Spravato, Invega Sustenna |
| Avadel Cns Pharmaceuticals, LLC | $193.17 | 2023-2025 | Lumryz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $187.67 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $80.31 | 2023-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $73.60 | 2023-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $70.15 | 2023-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $60.88 | 2023-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $60.88 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $30.78 | 2025 | Jornay Pm |
| Tris Pharma INC | $24.36 | 2023 | Dyanavel Xr |
| Bausch Health US, LLC | $16.35 | 2025 | Aplenzin, Wellbutrin |
| Azurity Pharmaceuticals, INC. | $15.95 | 2024 | Horizant |
| Biogen, INC. | $15.24 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.